Ratnakar Reddy Kuchukulla

Dr. Ratnakar Reddy Kuchukulla

Korea Institute of Science and Technology, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
PRP. Sambasiva Rao
P. Sambasiva Rao
GDG. Jitender Dev
G. Jitender Dev
YPY. Poornachandra
Y. Poornachandra
CKC. Ganesh Kumar
C. Ganesh Kumar
BNbanda narsaiah
banda narsaiah

14 October 2019 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
FLFuhai Li
Fuhai Li
ZHZe He
Ze He
LZLihong Zhou
Lihong Zhou
Qingle ZengQingle Zeng
Qingle Zeng
A recyclable Amberlyst-15-catalyzed three-component reaction in water was developed to synthesize asymmetric diarylmethyl sulfones in good to excellent yields with a wide substrate scope. Asymmetric diarylmethyl sulfones were prepared via C–C and C–S bond formation in a single step between easily available aryl/alkyl aldehydes, sodium aryl/alkyl sulfinates and tri/dimethoxybenzenes.

1 August 2015 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
YPY. Poornachandra
Y. Poornachandra
GDG. Jitender Dev
G. Jitender Dev
GMG. Mallareddy
G. Mallareddy
JNJagadeesh B. Nanubolu
Jagadeesh B. Nanubolu
BNbanda narsaiah
banda narsaiah

23 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
IHInjeoung Hwang
Injeoung Hwang
SPSang Won Park
Sang Won Park
SMSojeong Moon
Sojeong Moon
SKSuhn Hyung Kim
Suhn Hyung Kim
WHWooyoung Hur
Wooyoung Hur
HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50% of the patients respond poorly to trastuzumab, illustrating that novel therapy is warranted to overcome the resistance. We previously reported that in the majority of HER2+ breast-cancer patients, CDK12 is co-amplified on 17q12 and involved in developing tumors and trastuzumab resistance, proposing CDK12 as a potential drug target for HER2+ breast cancers. Here, we designed and synthesized novel 2,6,9-trisubstituted purines as potent CDK12 inhibitors showing strong, equipotent antiproliferative activity against trastuzumab-sensitive HER2+ SK-Br3 cells and trastuzumab-resistant HER2+ HCC1954 cells (GI50 values < 50 nM) both of which express a high level of CDK12. Two potent analogue 30d and 30e at 40, 200 nM greatly downregulated the levels of cyclinK and Pol II p-CTD (Ser2), as well as the expression of CDK12 downstream genes (IRS1 and WNT1) in a dose-dependent manner. We also observed structure-property relationship for a subset of potent analogues, and found that 30e is highly stable in liver microsomes with lack of CYP inhibition. In addition, 30d exhibited a synergy with trastuzumab in the both cells, suggesting that our inhibitors could be applied to alleviate trastuzumab-resistance of HER2+ breast cancers and escalate the efficacy of trastuzumab as well. Our study may provide insight into developing a novel therapy for HER2+ breast cancers.

18 May 2020 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
QTQinqin Tang
Qinqin Tang
YHYouming Huang
Youming Huang
ZHZe He
Ze He
LZLihong Zhou
Lihong Zhou
Qingle ZengQingle Zeng
Qingle Zeng

11 December 2017 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
RKRatnakar Reddy Kuchukulla
Ratnakar Reddy Kuchukulla
MDMadhu Desagoni
Madhu Desagoni
SNSrikanth Reddy Narra
Srikanth Reddy Narra
SGSanthosh Kumar Goutham
Santhosh Kumar Goutham
BNbanda narsaiah
banda narsaiah